期刊
CLINICAL AND EXPERIMENTAL MEDICINE
卷 15, 期 4, 页码 501-509出版社
SPRINGER-VERLAG ITALIA SRL
DOI: 10.1007/s10238-014-0319-0
关键词
Pancreas-derived mesenchymal stem cells (pMSCs); Reprogramming; PDX-1 mRNA; Insulin-producing cells (IPCs)
资金
- Major Science and Technology Projects of China [2013ZX10001-004-002-005]
- National Natural Science Foundation of China [21075097, 81070614]
- National Natural Science Foundation of Hubei province [2012FFA037]
- Natural Science Support Foundation for graduated students of Hubei University of Medicine [2011QDZR-8]
- Foundation of Hubei Educational Committee [B20122411]
Pancreatic islet transplantation has remained an effective therapy for type 1 diabetes since 2000. Its widespread use has been prohibited by the shortage of suitable donors. It is critical to explore an applicable alternative for beta-cell replacement. This study was performed to generate insulin-producing cells (IPCs) from pancreas-derived mesenchymal stem cells (pMSCs). pMSCs were isolated from discarded pancreatic tissue in the filter liquor during islet isolation procedure in mice and ex vivo expanded in culture. IPCs were induced by transfection of pancreas and duodenal transcription factor 1 (PDX-1) mRNA in vitro. Some islet characteristics were identified on pMSC-derived IPCs in mRNA and protein levels. Our results demonstrated that mouse pMSCs can be transdifferentiated into effective glucose-responsive insulin-producing cells through transfecting synthetic modified PDX-1 mRNA in vitro. The study of PDX-1 mRNA-induced pMSC reprogramming may pave the way toward the development of a novel beta-cell source for the treatment of diabetes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据